NCT05300048: Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 3 prior lines of systemic therapy for advanced/metastatic disease; Patients with prior exposure to serabelisib, Piqray/alpelisib, or other PIK3 kinase inhibitor; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑